CH638985A5 - Verfahren zur herstellung eines tollwutimpfstoffes und danach erhaltener impfstoff. - Google Patents
Verfahren zur herstellung eines tollwutimpfstoffes und danach erhaltener impfstoff. Download PDFInfo
- Publication number
- CH638985A5 CH638985A5 CH341479A CH341479A CH638985A5 CH 638985 A5 CH638985 A5 CH 638985A5 CH 341479 A CH341479 A CH 341479A CH 341479 A CH341479 A CH 341479A CH 638985 A5 CH638985 A5 CH 638985A5
- Authority
- CH
- Switzerland
- Prior art keywords
- vaccine
- rabies
- virus
- embryos
- embryo
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 73
- 238000000034 method Methods 0.000 title claims description 25
- 238000004519 manufacturing process Methods 0.000 title claims description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 title description 6
- 210000002257 embryonic structure Anatomy 0.000 claims description 28
- 241000272525 Anas platyrhynchos Species 0.000 claims description 25
- 229960003127 rabies vaccine Drugs 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 206010037742 Rabies Diseases 0.000 claims description 15
- 241000711798 Rabies lyssavirus Species 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 241000287828 Gallus gallus Species 0.000 claims description 10
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 9
- 238000003306 harvesting Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 238000001085 differential centrifugation Methods 0.000 claims description 7
- 244000144977 poultry Species 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000000644 propagated effect Effects 0.000 claims description 4
- 241000286209 Phasianidae Species 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 241000700605 Viruses Species 0.000 description 45
- 210000001161 mammalian embryo Anatomy 0.000 description 31
- 210000004556 brain Anatomy 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 235000013601 eggs Nutrition 0.000 description 15
- 239000000725 suspension Substances 0.000 description 13
- 238000002255 vaccination Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 235000013330 chicken meat Nutrition 0.000 description 9
- 230000036512 infertility Effects 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 102000006386 Myelin Proteins Human genes 0.000 description 6
- 108010083674 Myelin Proteins Proteins 0.000 description 6
- 210000001840 diploid cell Anatomy 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000011005 laboratory method Methods 0.000 description 6
- 210000005012 myelin Anatomy 0.000 description 6
- 235000019624 protein content Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 210000001325 yolk sac Anatomy 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229960000380 propiolactone Drugs 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 241000272522 Anas Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229960004906 thiomersal Drugs 0.000 description 2
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000005010 torso Anatomy 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH341479A CH638985A5 (de) | 1979-04-10 | 1979-04-10 | Verfahren zur herstellung eines tollwutimpfstoffes und danach erhaltener impfstoff. |
| CA346,984A CA1127081A (en) | 1979-04-10 | 1980-03-04 | Process for the preparation of rabies vaccine and accordingly obtained vaccine |
| DE3009064A DE3009064C2 (de) | 1979-04-10 | 1980-03-10 | Verfahren zur Herstellung eines Tollwutimpfstoffes |
| GB8008105A GB2048066B (en) | 1979-04-10 | 1980-03-11 | Rabies vaccine |
| US06/136,722 US4255520A (en) | 1979-04-10 | 1980-04-02 | Process for the preparation of a rabies vaccine and vaccine obtained by this process |
| FR8007854A FR2453651A1 (fr) | 1979-04-10 | 1980-04-08 | Procede de preparation d'un vaccin antirabique et vaccin obtenu suivant ce procede |
| BE0/200149A BE882684A (fr) | 1979-04-10 | 1980-04-08 | Procede de preparation d'un vaccin antirabique et vaccin obtenu suivant ce procede |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH341479A CH638985A5 (de) | 1979-04-10 | 1979-04-10 | Verfahren zur herstellung eines tollwutimpfstoffes und danach erhaltener impfstoff. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH638985A5 true CH638985A5 (de) | 1983-10-31 |
Family
ID=4255467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH341479A CH638985A5 (de) | 1979-04-10 | 1979-04-10 | Verfahren zur herstellung eines tollwutimpfstoffes und danach erhaltener impfstoff. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4255520A (enExample) |
| BE (1) | BE882684A (enExample) |
| CA (1) | CA1127081A (enExample) |
| CH (1) | CH638985A5 (enExample) |
| DE (1) | DE3009064C2 (enExample) |
| FR (1) | FR2453651A1 (enExample) |
| GB (1) | GB2048066B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3014189A1 (de) * | 1980-04-14 | 1981-10-15 | Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg | Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren |
| JPS6147187A (ja) * | 1984-08-10 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 狂犬病ウイルスの精製方法 |
| ATE69383T1 (de) * | 1985-11-22 | 1991-11-15 | Schweiz Serum & Impfinst | Verfahren zur herstellung eines tollwutimpfstoffes und nach diesem verfahren erhaltener impfstoff. |
| US20040023358A1 (en) * | 2001-12-21 | 2004-02-05 | Wyeth | Avian embryo particulate biomass for the production of virus antigens |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2204064A (en) * | 1938-05-13 | 1940-06-11 | Joseph W Beard | Equine encephalomyelitis vaccine |
| US2445300A (en) * | 1941-12-05 | 1948-07-13 | Univ Pennsylvania | Virus vaccines |
| US2506345A (en) * | 1946-10-01 | 1950-05-02 | American Cyanamid Co | Method of separating live viruses from nonviral protein matter |
| US2773800A (en) * | 1953-04-28 | 1956-12-11 | Lilly Co Eli | Rabies vaccine production |
| CH331368A (fr) * | 1953-08-21 | 1958-07-15 | American Cyanamid Co | Procédé pour atténuer le virus rabique virulent en une forme non pathogène sans perte appréciable de ses propriétés antigènes |
| US2768114A (en) * | 1953-08-21 | 1956-10-23 | American Cyanamid Co | Rabies vaccines and methods of preparing the same |
| US3155589A (en) * | 1958-04-14 | 1964-11-03 | Upjohn Co | Parenteral extravascular injectable vaccines for simultaneous immunization of canidae against rabies, canine distemper, and infectious canine hepatitis |
| US3029190A (en) * | 1959-08-04 | 1962-04-10 | Hanson Robert Paul | Selection of neurotropic viral strains and preparation of vaccines therefrom |
| US3143470A (en) * | 1961-04-24 | 1964-08-04 | Parke Davis & Co | Rabies virus propagation in embryonic cells maintained in a medium containing pancreatic digest of casein |
| US3156620A (en) * | 1962-01-10 | 1964-11-10 | American Cyanamid Co | Attenuated live rabies vaccine and method of preparing the same |
| US3255080A (en) * | 1962-08-06 | 1966-06-07 | Dow Chemical Co | Live rabies virus vaccine and method for the production thereof |
| US3397267A (en) * | 1964-09-21 | 1968-08-13 | Research Corp | Method of producing rabies vaccine |
| US3415926A (en) * | 1966-03-09 | 1968-12-10 | American Home Prod | Equine encephalomyelitis vaccine |
| US3859168A (en) * | 1967-06-22 | 1975-01-07 | Behringwerke Ag | Process of inactivating rabies virus |
| US3585266A (en) * | 1969-02-24 | 1971-06-15 | Dow Chemical Co | Live rabies virus vaccine and method for the production thereof |
| US3674862A (en) * | 1970-04-02 | 1972-07-04 | Lilly Co Eli | Live attenuated rabies virus vaccine and process therefor |
| US3973000A (en) * | 1972-02-04 | 1976-08-03 | Eli Lilly And Company | Process for purified rabies vaccine |
| FR2201079A1 (en) * | 1972-09-22 | 1974-04-26 | Inst Francais D Immunologie | Viruses prepn. by fractional centrifugation - using liquids of graded densities to displace impurities |
| US4071618A (en) * | 1974-09-03 | 1978-01-31 | Research Foundation For Microbial Diseases Of Osaka University | Process for preparing virus disease live vaccines |
| US4040904A (en) * | 1975-07-21 | 1977-08-09 | Slater Eban A | Novel rabies virus vaccine and processes |
| DE2616407C3 (de) * | 1976-04-14 | 1980-02-21 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Tollwut-Impfstoffs |
-
1979
- 1979-04-10 CH CH341479A patent/CH638985A5/de not_active IP Right Cessation
-
1980
- 1980-03-04 CA CA346,984A patent/CA1127081A/en not_active Expired
- 1980-03-10 DE DE3009064A patent/DE3009064C2/de not_active Expired
- 1980-03-11 GB GB8008105A patent/GB2048066B/en not_active Expired
- 1980-04-02 US US06/136,722 patent/US4255520A/en not_active Expired - Lifetime
- 1980-04-08 BE BE0/200149A patent/BE882684A/fr not_active IP Right Cessation
- 1980-04-08 FR FR8007854A patent/FR2453651A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| US4255520A (en) | 1981-03-10 |
| DE3009064A1 (de) | 1980-10-23 |
| DE3009064C2 (de) | 1984-01-12 |
| GB2048066B (en) | 1983-04-20 |
| GB2048066A (en) | 1980-12-10 |
| BE882684A (fr) | 1980-10-08 |
| CA1127081A (en) | 1982-07-06 |
| FR2453651A1 (fr) | 1980-11-07 |
| FR2453651B1 (enExample) | 1983-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69327307T2 (de) | Herstellung von antigenen und impfstoffen vom mysterie-disease-virus, antigene und erworbene impfstoffe zur verhinderung dieser krankheit | |
| EP0222974B1 (de) | Verfahren zur Herstellung eines Tollwutimpfstoffes und nach diesem Verfahren erhaltener Impfstoff | |
| DE3882599T2 (de) | Hundecoronavirus-Impfstoff. | |
| DE2516274C2 (de) | Verfahren zum Herstellen eines abgeschwächten Zytomegalie-Virus-Impfstoffes | |
| DE69923470T2 (de) | Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion | |
| DE2713371C2 (enExample) | ||
| DE1617940A1 (de) | Zellstaemme | |
| DE2463143C2 (de) | Polyvalente Rindervirus-Lebendimpfstoffe | |
| DE3786301T2 (de) | Kombinierter Impfstoff. | |
| CH658192A5 (de) | Tollwut-impfstoff und verfahren zu seiner herstellung. | |
| DE3009064C2 (de) | Verfahren zur Herstellung eines Tollwutimpfstoffes | |
| DE1198489B (de) | Verfahren zur Herstellung eines Impfstoffes gegen Panleucopenie | |
| DE1176317B (de) | Verfahren zur Herstellung von fuer Impf-zwecke geeigneten waessrigen Fluessigkeiten mit Tollwut-Virus | |
| DE2456636A1 (de) | Influenza-vakzine und verfahren zu ihrer herstellung | |
| DE3524794A1 (de) | Pharmazeutisches praeparat enthaltend lebende vermehrungsfaehige embryonalzellen, verfahren zu dessen herstellung und testverfahren zur bestimmung der pharmazeutischen wirksamkeit | |
| DE2034118A1 (en) | Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins | |
| DE1235505B (de) | Verfahren zur Herstellung einer Vaccine gegen Staupe | |
| DE2162013C3 (de) | Tollwut-Lebendimpfstoff, Verfahren zu seiner Herstellung nd seine Verwendung bei der Bekämpfung von Tollwut | |
| DE908909C (de) | Verfahren zur Herstellung und Verarbeitung pathogener Viren und der sie begleitenden Stoffe | |
| AT234902B (de) | Verfahren zur Herstellung einer Vaccine gegen Staupe | |
| DE2517550C3 (de) | Verfahren zum Herstellen eines Lebend-Impfstoffs zum Immunisieren von fleischfressenden Tieren gegen Staupe | |
| DE1007473B (de) | Verfahren zur Herstellung eines Poliomyelitis-Impfstoffes | |
| DE1021128B (de) | Verfahren zur Herstellung eines Impfstoffes gegen die Rhinotracheitis der Rinder | |
| DE1138888B (de) | Verfahren zur Herstellung einer Vaccine gegen Staupe | |
| AT225848B (de) | Verfahren zur Bestimmung von Antikörpern infektiöser Hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |